Successful Treatment With Dabrafenib (GSK2118436) in a Patient With Ganglioglioma

Kent C. Shih(Sarah Cannon), Mythili Shastry(Sarah Cannon), Jeffrey T. Williams(Saint Thomas Health), Peter F. Jelsma(Saint Thomas Health), Steven R. Abram(Saint Thomas Health), Kanyalakshmi Ayyanar(University of Louisville), Howard A. Burris(Sarah Cannon), Jeffrey R. Infante(Sarah Cannon)
Journal of Clinical Oncology
February 11, 2014
10.1200/jco.2013.48.6852
Cited by 30Open Access
Full Text

Abstract

Related Papers

Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
Axel Hauschild, Jean‐Jacques Grob, Lev Demidov et al.|The Lancet|2012|3k
Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial
Gerald S. Falchook, Georgina V. Long, Razelle Kurzrock et al.|The Lancet|2012|933
Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial
Georgina V. Long, Uwe Trefzer, Michael A. Davies et al.|The Lancet Oncology|2012|905
Supratentorial gangliogliomas: Histopathologic grading and tumor recurrence in 184 patients with a median follow‐up of 8 years
Cordelia Luyken, Ingmar Blümcke, Rolf Fimmers et al.|Cancer|2004|346
Activating mutations in BRAF characterize a spectrum of pediatric low-grade gliomas
Margaret Dougherty, Mariarita Santi, Marcia S. Brose et al.|Neuro-Oncology|2010|322